Table 2.
Risk of outcomes for eligible COVID-19 patients with advanced kidney disease receiving nirmatrelvir-ritonavir compared with molnupiravir.
| Outcomes | Total (N = 4886) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nirmatrelvir-ritonavir (N = 1462) |
Molnupiravir (N = 3424) |
ARR (95% CI) (%) | Adjusted HR (95% CI)a | |||||||
| Events | Rate (%) | Follow-up time (days) | Incidence rate (per 10,000 person days) | Events | Rate (%) | Follow-up time (days) | Incidence rate (per 10,000 person days) | |||
| All-cause mortality | 74 | 5.06 | 127,047 | 5.82 (4.57, 7.31) | 273 | 7.97 | 291,056 | 9.38 (8.30, 10.56) | 2.91 (1.47, 4.36) | 0.624 (0.455–0.857) |
| ICU admission | 4 | 0.27 | 126,933 | 0.32 (0.09, 0.81) | 6 | 0.18 | 290,866 | 0.21 (0.08, 0.45) | −0.09 (−0.40, 0.20) | NAb |
| Ventilatory support | 13 | 0.89 | 126,588 | 1.03 (0.55, 1.76) | 35 | 1.02 | 290,024 | 1.21 (0.84, 1.68) | 0.13 (−0.45, 0.72) | 0.547 (0.124–2.407) |
| Hospitalisation | 218 | 23.98 | 66,252 | 32.90 (28.68, 37.57) | 618 | 28.14 | 153,343 | 40.30 (37.19, 43.61) | 4.16 (0.81, 7.51) | 0.782 (0.64–0.954) |
| Hepatic impairment | 0 | 0.00 | 126,507 | 0.00 (0.00, 0.29) | 1 | 0.03 | 290,236 | 0.03 (0.00, 0.19) | 0.03 (−0.03, 0.09) | NAb |
| Ischaemic stroke | 3 | 0.22 | 119,199 | 0.25 (0.05, 0.74) | 5 | 0.16 | 272,990 | 0.18 (0.06, 0.43) | −0.06 (−0.35, 0.22) | NAb |
| Myocardial infarction | 2 | 0.15 | 119,761 | 0.17 (0.02, 0.60) | 7 | 0.22 | 272,596 | 0.26 (0.10, 0.53) | 0.07 (−0.19, 0.33) | NAb |
ARR, Absolute risk reduction; HR, Hazard ratio; CI, Confidence interval; ICU, Intensive care units; NA, Not applicable.
a
Hazard ratios were obtained from stratified Cox proportional hazard regression adjusted by sex, age, Charlson Comorbidity Index, vaccination status, hospitalisation, eGFR, renal replacement therapy, pre-existing comorbidities and medication use within 90 days at baseline.
b
Not applicable due to insufficient events observed.